Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Kentucky Retirement Systems

Kentucky Retirement Systems trimmed its stake in Hologic, Inc. (NASDAQ:HOLX) by 1.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,961 shares of the medical equipment provider’s stock after selling 220 shares during the quarter. Kentucky Retirement Systems’ holdings in Hologic were worth $1,151,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. State Street Corp increased its position in Hologic by 0.8% during the 3rd quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock worth $847,944,000 after purchasing an additional 81,057 shares in the last quarter. FMR LLC boosted its stake in shares of Hologic by 64.0% during the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after purchasing an additional 2,174,093 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Hologic by 0.7% during the third quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider’s stock worth $208,051,000 after buying an additional 18,774 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in shares of Hologic by 8.6% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,466,888 shares of the medical equipment provider’s stock valued at $200,952,000 after buying an additional 195,285 shares during the last quarter. Finally, Nordea Investment Management AB lifted its stake in shares of Hologic by 32.7% during the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock valued at $159,911,000 after buying an additional 544,889 shares during the period. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now owns 27,957 shares in the company, valued at $2,134,237.38. This represents a 47.06 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.88% of the company’s stock.

Hologic Price Performance

HOLX opened at $64.47 on Monday. The company has a 50 day moving average of $69.91 and a two-hundred day moving average of $76.53. Hologic, Inc. has a 52-week low of $62.69 and a 52-week high of $84.67. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The company has a market cap of $14.47 billion, a P/E ratio of 20.34, a P/E/G ratio of 2.14 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on HOLX. William Blair reaffirmed an “outperform” rating on shares of Hologic in a research note on Thursday, February 6th. Leerink Partnrs downgraded Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. BNP Paribas upgraded Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Needham & Company LLC lowered Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target on the stock. in a research note on Monday, February 3rd. Finally, Mizuho dropped their price objective on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. Ten analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $85.77.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.